Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

LungVax

- PMLiVE

Cancer researchers investigate why smouldering myeloma progresses

Around 6,500 people are diagnosed with myeloma in the UK each year

- PMLiVE

AstraZeneca’s Tagrisso shows eight-year landmark survival in early-stage EGFR-mutated lung cancer

The results from a global phase 3 trial show the longest survival data ever reported in this setting

- PMLiVE

Pfizer’s Lorviqua recommended by NICE for lung cancer

Lung cancer is the leading cause of cancer-related deaths worldwide

- PMLiVE

Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients

Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year

EU flag

CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

- PMLiVE

AstraZeneca shares late-stage results for Tagrisso combination in lung cancer

An estimated 2.4 million people globally are diagnosed with lung cancer each year

- PMLiVE

FDA approves Dizal’s oral therapy Zegfrovy to treat advanced lung cancer

Around 226,650 new cases of lung cancer are expected to be diagnosed in the US this year

- PMLiVE

MHRA approves Accord Healthcare’s Hetronifly to treat aggressive form of lung cancer

Small cell lung cancer accounts for up to 15% of all lung cancer diagnoses

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer

Approximately 226,650 new cases of lung cancer will be diagnosed in the US this year

- PMLiVE

Roche/Jazz share positive phase 3 results for lung cancer combination therapy

Approximately 30,000 new cases of small cell lung cancer are reported in the US every year

- PMLiVE

Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC

Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection

- PMLiVE

Pfizer gains rights to 3SBio’s investigational bispecific antibody in deal worth over $6bn

The candidate is in clinical development for colorectal cancer, lung cancer and gynaecological tumours

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links